Aptevo Therapeutics Inc.
APVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001671584
No open-market purchases or sales by Aptevo Therapeutics Inc. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $224.3K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Aptevo Therapeutics Inc. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −1 vs. Q1 2023
- Shares held
- 928.8K
- +37.2K (+4.2%) vs. Q1 2023
- Total value
- $1.36M
- −$456.2K (−25.1%) vs. Q1 2023
- New holders
- 2
- 3 more added
- Sold out
- 3
- 2 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting APVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $224.3K |
| Q1 2026 | 9 | $229.7K |
| Q4 2025 | 11 | $191.4K |
| Q3 2025 | 12 | $717.1K |
| Q2 2025 | 7 | $45.9K |
| Q1 2025 | 8 | $22.8K |
| Q4 2024 | 13 | $208.7K |
| Q3 2024 | 19 | $231.1K |
| Q2 2024 | 18 | $599.1K |
| Q1 2024 | 10 | $12.4K |
| Q4 2023 | 29 | $349.7K |
| Q3 2023 | 26 | $1.13M |
| Q2 2023 | 23 | $1.36M |
| Q1 2023 | 24 | $1.82M |
| Q4 2022 | 27 | $2.27M |
| Q3 2022 | 27 | $2.63M |
| Q2 2022 | 27 | $2.85M |
| Q1 2022 | 24 | $4.76M |
| Q4 2021 | 23 | $5.99M |
| Q3 2021 | 26 | $42.1M |
| Q2 2021 | 29 | $65.5M |
| Q1 2021 | 34 | $89.7M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Aptevo Therapeutics Inc.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 6 | $9 | 0.00% | 00.0% | Unchanged |
| Citigroup Inc | 10 | $15 | 0.00% | 00.0% | Unchanged |
| Earnest Partners LLC | 14 | $20 | 0.00% | 00.0% | Unchanged |
| Allworth Financial LP | 17 | $25 | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 30 | $43 | 0.00% | 00.0% | Unchanged |
| Truvestments Capital LLC | 95 | $139 | 0.00% | 00.0% | Unchanged |
| The PNC Financial Services Group, Inc. | 142 | $207 | 0.00% | 00.0% | Unchanged |
| Fifth Third Bancorp | 291 | $425 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,490 | $2.17K | 0.00% | +1,490 | New |
| Wells Fargo & Company | 1,531 | $2.23K | 0.00% | −83−5.1% | Reduced |
| State Street Corp | 10,941 | $16.0K | 0.00% | 00.0% | Unchanged |
| Franklin Resources Inc | 10,997 | $16.1K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 11,013 | $16.1K | 0.00% | 00.0% | Unchanged |
| Bank of Montreal | 10,000 | $17.8K | 0.00% | 00.0% | Unchanged |
| Citadel Advisors LLC | 12,782 | $18.7K | 0.00% | +12,782 | New |
| Northern Trust Corp | 17,642 | $25.8K | 0.00% | 00.0% | Unchanged |
| Price T Rowe Associates Inc | 46,200 | $68.0K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 48,046 | $70.1K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 52,825 | $77.1K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 80,186 | $117.0K | 0.00% | +25,200+45.8% | Added |
| Schonfeld Strategic Advisors LLC | 144,600 | $211.1K | 0.00% | +800+0.6% | Added |
| Vanguard Group Inc | 228,824 | $334.1K | 0.00% | −536−0.2% | Reduced |
| Cantor Fitzgerald, L. P. | 251,122 | $366.6K | 0.01% | +32,422+14.8% | Added |
| Bank of New York Mellon Corp | 0 | $0 | 0.00% | −20,555−100.0% | Sold out |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −12,612−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −1,700−100.0% | Sold out |